MARKET

PLX

PLX

PROTALIX BIOTHER
AMEX

Real-time Quotes | Nasdaq Last Sale

2.890
+0.150
+5.47%
Closed 19:59 05/17 EDT
OPEN
2.750
PREV CLOSE
2.740
HIGH
2.960
LOW
2.700
VOLUME
3.10M
TURNOVER
--
52 WEEK HIGH
7.02
52 WEEK LOW
2.610
MARKET CAP
131.16M
P/E (TTM)
-12.9133
1D
5D
1M
3M
1Y
5Y
DAFNA Capital Management LLC Buys Morphic Holding Inc, Revolution Medicines Inc, Protalix ...
GuruFocus News · 12h ago
Protalix swings to Q1 net loss, but beats on EPS and revenue estimates
Although Protalix BioTherapeutics (PLX) swung to a net loss of $5.5M in Q1 from net income of $1.7M in the prior-year period, the company managed to beat analyst expectations.Revenue dropped
Seekingalpha · 3d ago
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 3d ago
BRIEF-Protalix Biotherapeutics Reports Q1 Loss Per Share Of $0.14
reuters.com · 3d ago
Protalix BioTherapeutics EPS beats by $0.03, beats on revenue
Protalix BioTherapeutics (PLX): Q1 GAAP EPS of -$0.14 beats by $0.03.Revenue of $11.32M (-47.7% Y/Y) beats by $6.37M.Shares +4.2% PM.Press Release
Seekingalpha · 3d ago
Protalix BioTherapeutics Q1 EPS $(0.14) Beats $(0.17) Estimate, Sales $11.32M Beat $10.95M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 240 percent decrease over earnings of $0.10 per share
Benzinga · 3d ago
Protalix BioTherapeutics Reports First Quarter 2021 Financial Results and Business Update
CARMIEL, , /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ...
PR Newswire - PRF · 3d ago
Protalix Biotherapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2021 / Protalix Biotherapeutics, Inc. (NYSE:PLX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 14, 2021 at 8:30 AM Eastern Time.
ACCESSWIRE · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLX. Analyze the recent business situations of PROTALIX BIOTHER through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLX stock price target is 11.00 with a high estimate of 15.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 32
Institutional Holdings: 12.41M
% Owned: 27.35%
Shares Outstanding: 45.38M
TypeInstitutionsShares
Increased
6
1.51M
New
7
1.67M
Decreased
3
89.21K
Sold Out
9
231.97K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Director
Zeev Bronfeld
President/Chief Executive Officer/Director
.. ..
President/Chief Executive Officer/Director
Dror Bashan
Chief Financial Officer/Senior Vice President
Eyal Rubin
Senior Vice President
Einat Almon
Senior Vice President
Yaron Naos
Vice President - Research & Development
Yael Hayon
Director
Pol Boudes
Director
Gwen Melincoff
Independent Director
Amos Bar-Shalev
Independent Director
David Granot
Independent Director
Aharon Schwartz
No Data
About PLX
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.

Webull offers kinds of Protalix Biotherapeutics Inc stock information, including AMEX:PLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLX stock methods without spending real money on the virtual paper trading platform.